Exclusive video interview: David Wood demystifies the transhumanist agenda

As Longevity moves quickly into the mainstream there are terms and legacies that some use to challenge the sector’s validity: we explore what it means to be a transhumanist.

David Wood is on the Board of Directors of the Institute for Ethics and Emerging Technologies and as Chair of London Futurists, David has organised regular meetings in London since 2008 covering: futurist; transhumanist; techno-progressive; and singularitarian matters.

Longevity.Technology: Back in April, when we ran our digital conference Longevity 2020, David Wood was a key participant in the ask-me-anything sessions: his questions were on-point and his comments articulate:

In this exclusive video interview, we explore which technologies will have the greatest impact on human beings in the 21st century and NBIC interconnections:

  • Nanotech … control at the nanoscale – this domain will include quantum in the future;
  • Biotech … gene editing, epigenome, proteome and regenerative technologies;
  • Infotech … AI, biotech, and digital systems that move us closer to the Singularity;
  • Cognotech (Neurotech) … interconnections between neurons and digital tech, at this stage the least developed, but with potential to have the most profound impact.

David talks about Covid-19 and the crisis of mental health and how healthy aging is about individuals continuing to have a rich connection to society:

Phil Newman
Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of Crowd Longevity a digital investment platform for international investors and Longevity start-ups launching in 2020.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

Latest articles

Big Brother approach to accelerate preclinical studies

Tracked.bio develops AI computer vision system that tracks flies and mice to reduce man-hours and increase data collected in Longevity studies. A Danish start-up aims...

Deliver us from aging – the Quicksilver method

Bigger certainly doesn't mean better when it comes to Quicksilver's nutraceutical delivery methods. The COVID-19 pandemic has caused an upturn in the supplements industry; from...

Astellas to acquire iota Biosciences

Following an R&D collaboration that began last year, Japanese pharma Astellas has announced it will acquire bioelectronics firm iota in $304m deal. Last year's R&D...

OneSkin launches topical senetherapeutic skin treatment

Extending skinspan with non-invasive senetherapeutic proprietary peptide. OneSkin is a Longevity company on a mission to transform the way we think about skin. Today the...